For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230928:nRSb0223Oa&default-theme=true
RNS Number : 0223O Kromek Group PLC 28 September 2023
28 September 2023
Kromek Group plc
("Kromek" or the "Group")
Result of AGM
Kromek Group plc, a leading developer of radiation and bio-detection
technology solutions for the advanced imaging and CBRN detection segments,
announces that at its Annual General Meeting ("AGM"), held earlier today, all
resolutions were duly passed.
Details of the proxy voting results, which should be read alongside the Notice
of AGM, are below:
Resolution Votes for Votes against Votes withheld Total proxy votes
No. of votes % of votes cast* No. of votes % of votes cast* No. of votes
1 189,476,538 94.43 11,176,883 5.57 217,336 200,870,757
2 179,826,325 90.14 19,674,285 9.86 1,370,147 200,870,757
3 182,008,714 91.33 17,274,285 8.67 1,587,758 200,870,757
4 198,554,316 99.71 582,433 0.29 1,734,008 200,870,757
5 199,638,889 99.60 806,687 0.40 425,181 200,870,757
6 198,643,359 98.98 2,051,977 1.02 175,421 200,870,757
7 191,067,728 96.32 7,295,934 3.68 2,507,095 200,870,757
8 187,184,965 93.34 13,353,050 6.66 332,742 200,870,757
*Excludes withheld votes
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO +44 (0)1740 626 060
Paul Farquhar, CFO
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance +44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM
Michael Johnson/Tamar Cranford-Smith - Sales
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGEAENPAADDEFA